George D. Yancopoulos, M.D., Ph.D., is President and Chief Scientific Officer of Regeneron, where he has served as lead inventor and drug developer since the company's inception more than 30 years ago. Dr. Yancopoulos and his team are responsible for blockbuster treatments such as EYLEA(r) (for blindness-causing diseases) and Dupixent(r) (for asthma, atopic dermatitis and other allergic diseases), as well as dozens of other approved and promising investigational medicines for serious diseases such as Ebola and COVID-19. He received his M.D. and Ph.D. from Columbia University, was elected to the National Academy of Sciences in 2004, inducted into the Biotech Hall of Fame in 2014, and named E&Y's Entrepreneur of the Year in 2016.